Evexia Lifecare Ltd's 34th Annual General Meeting (AGM)

Evexia Lifecare Limited will hold its 34th Annual General Meeting (AGM) on May 15, 2026, convening virtually for shareholders to vote on pivotal expansion strategies. Among the key proposals is the authorization for the Board to make investments up to Rs. 2,000 crore and secure borrowings up to Rs. 1,000 crore, signaling a major shift in the company's direction.

Key Agenda Items at the AGM

The virtual AGM, scheduled for May 15, 2026, at 11:30 a.m. IST, will include standard business such as adopting audited financial statements for fiscal year 2024-25, re-appointing directors and auditors. However, the focus will be on crucial special resolutions. Shareholders will vote on amending the company's Memorandum of Association (MOA) to formally incorporate business in the electric vehicle (EV) sector. This move is accompanied by proposals to empower the Board with borrowing powers of up to Rs. 1,000 crore and the authority to make investments totaling Rs. 2,000 crore.

Why This Matters

This AGM marks a potential strategic pivot for Evexia Lifecare, a company historically engaged in pharmaceutical trading and chemical manufacturing. Venturing into the rapidly growing EV market and related infrastructure requires substantial capital and execution expertise. The proposed funding limits indicate a serious commitment to new ventures, and shareholder approval is critical for the company to formally enter the EV domain.

A History of Transformation

Evexia Lifecare, formerly known as Raghuvir Synthetics Ltd, has a history of strategic business shifts, including previous ventures into diamond trading. Its current core operations involve trading and distribution of pharmaceutical products and chemicals. This planned entry into electric vehicles represents a significant departure from its established areas, requiring the development of new competencies and market strategies.

What Changes Now

Shareholders will have the final say on the company's strategic direction, particularly its ambitious foray into the EV market. Approval of the MOA alteration and funding resolutions would empower management to pursue EV manufacturing, assembly, distribution, and infrastructure development. The proposed re-appointment of Mr. Jayesh Raichandbhai Thakkar as Managing Director for a further three years will ensure leadership continuity. Shareholders will also vote on the appointment of M/s Tejas K. Soni as the Statutory Auditor for FY25-26, ensuring compliance and financial oversight.

Potential Hurdles and Financial Indicators

Despite the growth potential in the EV sector, Evexia Lifecare faces considerable execution risks. Its background in pharmaceutical trading contrasts with the complexities of EV manufacturing, supply chains, and market penetration. Past financial performance also presents challenges: the company has shown historically low sales growth, a low return on equity, and a high number of debtor days. Furthermore, promoter holding has decreased in recent years. Successfully raising and deploying Rs. 2,000 crore will demand robust financial management and strategic planning to avoid inefficient capital allocation or significant dilution for existing shareholders.

Peer Comparison

While Evexia Lifecare is charting a new course, established players in the EV space include Tata Motors, Mahindra & Mahindra, and companies focused on charging infrastructure like Exicom Tele-Systems. These companies have years of experience in manufacturing, supply chain, and market penetration within the automotive and EV sectors.

Context Metrics

Evexia Lifecare reported a consolidated net profit of Rs. 0.29 crore for the quarter ended December 2025, a 141.67% increase from the previous quarter. For the quarter ended June 2025, consolidated net profit rose 162.50% to Rs. 0.63 crore compared to the prior quarter.

What to Track Next

Shareholders' decisions at the May 15th AGM regarding the EV expansion and funding limits will be the primary trigger. Watch for specific announcements detailing Evexia Lifecare's strategic roadmap for EV manufacturing, charging infrastructure development, and potential partnerships. Detailed financial results for FY 2024-25, to be adopted at the AGM, will offer insights into the company's current performance. Any updates on the utilization of the approved funds and the timeline for commencing EV-related operations will also be key.